On June 8th, 2019, Medtronic plc, an international leader in medical technology, announced that it has started a crucial trial for its next-generation Guardian™ continuous glucose monitoring (CGM) sensor.
The CGM sensor has been developed to lower sensor calibrations, enhance precision and overall system performance, and improve overall user experience.
The multicenter, impending trial will analyze the next-generation CGM sensor in almost 460 Type 1 or 2 diabetic participants aged 2–80 years for a period of seven days. Participants involved in the study will be assigned to sensor wear location and testing days and times at random.
We are very excited about this next-generation CGM sensor as it is designed to require calibrations only on the first day of wear, reducing fingersticks by 95% over our current CGM. We strongly believe calibration on the first day of wear is necessary to improve day one performance, which we know from physician and patient feedback is a challenge for all sensors. Our research shows this day one performance is critical for keeping patients safe in hybrid closed loop, or Auto Mode, which we know from real-world experience delivers the optimal Time in Range for patients on insulin therapy.
Ali Dianaty, Vice President, Research & Development, Diabetes Group, Medtronic
This is a very positive next step to enhancing the overall experience with Medtronic hybrid closed loop systems with enhanced sensors that really focus on the patient experience. It’s great to see that these advancements are being informed by robust real-world use of Medtronic therapies with an emphasis on ensuring that these important technologies are not only delivering best-in-class outcomes but also prioritizing ease of use.
Dr Bruce Bode, Clinical Associate Professor, Department of Medicine, Emory University
Bode is also the co-principal investigator of the research.